Given the limitations of in-vitro or pre-clinical studies of blueberry mechanisms, there is also a need for additional human biomarker studies to understand whether cognitive benefits arise from antioxidant effects, metabolic effects, anti-inflammatory effects, protection from neurotoxins or through altering other pathways implicated in AD/MCI such as beta-amyloid and tau. This evidence concerns the gene MAPT and Alzheimer disease.